Current Report Filing (8-k)
October 20 2020 - 8:01AM
Edgar (US Regulatory)
UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
WASHINGTON, D.C. 20549
FORM 8-K
CURRENT REPORT
Pursuant to Section 13 or 15(d)
of the Securities Exchange Act of 1934
Date of Report (Date of Earliest Event
Reported): October 20, 2020
APTINYX INC.
(Exact name of registrant as specified
in its charter)
Delaware
|
|
001-38535
|
|
47-4626057
|
(State or other jurisdiction
of incorporation)
|
|
(Commission
File Number)
|
|
(I.R.S. Employer
Identification No.)
|
909 Davis Street, Suite 600
Evanston, IL 60201
(Address of principal executive offices,
including zip code)
(847) 871-0377
(Registrant’s telephone number, including
area code)
Not Applicable
(Former Name or Former Address, if Changed
Since Last Report)
Check the appropriate box below if the Form 8-K filing
is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:
¨
|
Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)
|
¨
|
Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)
|
¨
|
Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))
|
¨
|
Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))
|
Securities registered pursuant to Section 12(b) of
the Act:
Title of each class
|
Trading symbol(s)
|
Name of each exchange on which registered
|
Common Stock, par value $0.01 per share
|
APTX
|
The Nasdaq Global Select Market
|
Indicate by check mark whether the registrant is an emerging
growth company as defined in Rule 405 of the Securities Act of 1933 (§230.405 of this chapter) or Rule 12b-2 of
the Securities Exchange Act of 1934 (§240.12b-2 of this chapter).
Emerging growth company x
If an emerging growth company, indicate by check mark if the
registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards
provided pursuant to Section 13(a) of the Exchange Act. ¨
On October 19, 2020, Aptinyx Inc.
(the “Company”) announced top-line data from the Company’s Phase 2 study of NYX-783 in patients with post-traumatic
stress disorder. A copy of the slide presentation relating to these data is being filed herewith as Exhibit 99.1 to this Current
Report on Form 8-K and is incorporated herein by reference. The Company undertakes no obligation to update, supplement or
amend the materials attached hereto as Exhibit 99.1.
Item 9.01 Financial Statements and Exhibits.
(d) Exhibits
SIGNATURES
Pursuant to the requirements of the Securities Exchange Act
of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.
|
Aptinyx Inc.
|
|
|
|
Date: October 20, 2020
|
By:
|
/s/ Ashish Khanna
|
|
|
Ashish Khanna
|
|
|
Chief Financial Officer and Chief Business Officer
|
Aptinyx (NASDAQ:APTX)
Historical Stock Chart
From Mar 2024 to Apr 2024
Aptinyx (NASDAQ:APTX)
Historical Stock Chart
From Apr 2023 to Apr 2024